TY - JOUR
T1 - Direct reprogramming of cardiomyocytes into cardiac Purkinje-like cells
AU - Prodan, Nicole
AU - Ershad, Faheem
AU - Reyes-Alcaraz, Arfaxad
AU - Li, Luge
AU - Mistretta, Brandon
AU - Gonzalez, Lei
AU - Rao, Zhoulyu
AU - Yu, Cunjiang
AU - Gunaratne, Preethi H.
AU - Li, Na
AU - Schwartz, Robert J.
AU - McConnell, Bradley K.
N1 - The authors would like to acknowledge Alon R. Azares (Texas Heart Institute, Houston TX) for his assistance with the FACS experiments and Dr. Jean J. Kim (Baylor College of Medicine, Houston TX) for her assistance in training N.P. on culturing iPSCs through the “Basics of Human Pluripotent Stem Cells” course. This article is in partial fulfillment of the requirements for a Ph.D. (Pharmacology) in the Department of Pharmacological and Pharmaceutical Sciences in the College of Pharmacy at the University of Houston (N.P.). Research reported in this article was supported in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under award numbers R15 HL141963 (B.K.M.), R01 HL136389 , R01 HL163277 and R01 HL147108 (N.L.); the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the NIH under award numbers R21 EB026175 (C.Y.) and 1R21 EB030257-01 (C.Y.); the National Science Foundation under award number 1936151 (C.Y.); the American Heart Association (AHA) under award number 18AIREA 33960175 (B.K.M.) and EIA93611 (N.L.); and a grant from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (B.K.M.). Also, the research reported in this article was supported in part by a University of Houston (UH)/ Baylor College of Medicine (BCM) Collaborative Pilot Grant (B.K.M., N.L.). The funders had no role in the preparation of the article or the decision to publish this article.
PY - 2022/11/18
Y1 - 2022/11/18
N2 - Currently, there are no treatments that ameliorate cardiac cell death, the underlying basis of cardiovascular disease. An unexplored cell type in cardiac regeneration is cardiac Purkinje cells; specialized cells from the cardiac conduction system (CCS) responsible for propagating electrical signals. Purkinje cells have tremendous potential as a regenerative treatment because they may intrinsically integrate with the CCS of a recipient myocardium, resulting in more efficient electrical conduction in diseased hearts. This study is the first to demonstrate an effective protocol for the direct reprogramming of human cardiomyocytes into cardiac Purkinje-like cells using small molecules. The cells generated were genetically and functionally similar to native cardiac Purkinje cells, where expression of key cardiac Purkinje genes such as CNTN2, ETV1, PCP4, IRX3, SCN5a, HCN2 and the conduction of electrical signals with increased velocity was observed. This study may help to advance the quest to finding an optimized cell therapy for heart regeneration.
AB - Currently, there are no treatments that ameliorate cardiac cell death, the underlying basis of cardiovascular disease. An unexplored cell type in cardiac regeneration is cardiac Purkinje cells; specialized cells from the cardiac conduction system (CCS) responsible for propagating electrical signals. Purkinje cells have tremendous potential as a regenerative treatment because they may intrinsically integrate with the CCS of a recipient myocardium, resulting in more efficient electrical conduction in diseased hearts. This study is the first to demonstrate an effective protocol for the direct reprogramming of human cardiomyocytes into cardiac Purkinje-like cells using small molecules. The cells generated were genetically and functionally similar to native cardiac Purkinje cells, where expression of key cardiac Purkinje genes such as CNTN2, ETV1, PCP4, IRX3, SCN5a, HCN2 and the conduction of electrical signals with increased velocity was observed. This study may help to advance the quest to finding an optimized cell therapy for heart regeneration.
KW - Bioengineering
KW - Cell biology
KW - Stem cells research
UR - http://www.scopus.com/inward/record.url?scp=85141226503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141226503&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2022.105402
DO - 10.1016/j.isci.2022.105402
M3 - Article
AN - SCOPUS:85141226503
SN - 2589-0042
VL - 25
JO - iScience
JF - iScience
IS - 11
M1 - 105402
ER -